Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TLIS - Talis Biomedical Corp


IEX Last Trade
4.41
4.410   100.000%

Share volume: 0
Last Updated: Fri 30 Aug 2024 08:00:00 PM CEST
Surgical and Medical Instrument Manufacturing : 1.09%

PREVIOUS CLOSE
CHG
CHG%

N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
13%
Profitability 0%
Dept financing 11%
Liquidity 75%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
-15.69%
6 Months
-79.33%
1 Year
-77.55%
2 Year
-75.34%
Key data
Stock price
$4.41
P/E Ratio 
-0.16
DAY RANGE
N/A - N/A
EPS 
-$27.92
52 WEEK RANGE
$1.60 - $9.60
52 WEEK CHANGE
-$77.40
MARKET CAP 
7.984 M
YIELD 
N/A
SHARES OUTSTANDING 
1.823 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Robert J. Kelley
Region: US
Website: talisbio.com
Employees: 260
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Surgical and Medical Instrument Manufacturing
Sector: Manufacturing

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis 1 COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVI-19.

Recent news